Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
J Pharm Pharmacol ; 57(2): 205-11, 2005 Feb.
Article de Anglais | MEDLINE | ID: mdl-15720784

RÉSUMÉ

Two 1,2,4-substituted derivatives of piperazine were tested for their effect on dopamine and serotonin (5-HT) release in rat prefrontal cortex. Both compounds, 1-[4-(4-chinolin-2-yl-piperazin-1yl)-butyl]piperidin-2-on (MM5) and 1-[4-(2-methyl-4-chinolin-2-yl-piperazin-1-yl)-butyl]-8-azaspiro [4.5]decano-7,9-dion (MC1), produced hypothermia in mice and showed affinity for 5-HT1A receptors in-vitro. Like the selective 5-HT1A agonist 8-OH-DPAT (0.1 mg kg(-1)), MM5 given peripherally (30 mg kg(-1)) decreased the extracellular 5-HT level in rat prefrontal cortex, while MC1 suppressed 5-HT release at a higher dose (40 mg kg(-1)), but not at a lower one (30 mg kg(-1)). The effect of both compounds on 5-HT release was abolished by WAY 100635 (0.3 mg kg(-1)). MC1 (30 and 40 mg kg(-1)), but not MM5, raised cortical dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and extracellular homovanillic acid (HVA) levels. The effect of MC1 on dopamine release was reversed by neither WAY 100635 nor the non-selective 5-HT2 antagonist ritanserin (2 mg kg(-1)). However, ritanserin prevented the effect of the higher dose of MC1 on 5-HT release. The results of this study suggest that MM5 exhibits the profile of a 5-HT1A agonist devoid of dopaminergic activity. MC1 seems to possess moderate agonist activity at 5-HT1A and 5-HT2A receptors, while acting on 5-HT release in the rat prefrontal cortex. However, the facilitation of dopamine release by this compound does not seem to be related to its affinity for 5-HT1A and 5-HT2A receptors.


Sujet(s)
Dopamine/physiologie , Pipérazines/pharmacologie , Pipéridones/pharmacologie , Cortex préfrontal/effets des médicaments et des substances chimiques , Cortex préfrontal/physiologie , Sérotonine/physiologie , Spiranes/pharmacologie , Acide 3,4-dihydroxy-benzèneacétique/composition chimique , Acide 3,4-dihydroxy-benzèneacétique/métabolisme , 7-Dipropylamino-5,6,7,8-tétrahydro-1-naphtol/pharmacologie , Animaux , Dopamine/composition chimique , Liquide extracellulaire/composition chimique , Liquide extracellulaire/effets des médicaments et des substances chimiques , Liquide extracellulaire/métabolisme , Acide homovanillique/composition chimique , Acide homovanillique/métabolisme , Mâle , Microdialyse/méthodes , Pipérazines/antagonistes et inhibiteurs , Pipérazines/composition chimique , Pipérazines/métabolisme , Pipéridones/métabolisme , Pologne , Cortex préfrontal/composition chimique , Pyridines/pharmacologie , Dosage par compétition/méthodes , Rats , Rat Wistar , Récepteur de la sérotonine de type 5-HT1A/effets des médicaments et des substances chimiques , Récepteur de la sérotonine de type 5-HT1A/physiologie , Récepteur de la sérotonine de type 5-HT2A/effets des médicaments et des substances chimiques , Récepteur de la sérotonine de type 5-HT2A/physiologie , Ritansérine/pharmacologie , Sérotonine/composition chimique , Agonistes des récepteurs 5-HT1 de la sérotonine , Agonistes des récepteurs 5-HT2 de la sérotonine , Spiranes/métabolisme , Relation structure-activité
2.
Acta Pol Pharm ; 60(2): 141-4, 2003.
Article de Anglais | MEDLINE | ID: mdl-13678325

RÉSUMÉ

HPLC conditions for the identification of stereoisomers and stereochemical purity of the key intermediate in Trandolapril synthesis, octahydro-1H-indole-2-carboxylic acid, and final drug were elaborated. The chemical and stereochemical purity of synthetic Trandolapril was proved to be as high as 99.3-99.8%, on both non chiral and chiral RP-columns.


Sujet(s)
Acides carboxyliques/analyse , Acides carboxyliques/composition chimique , Indoles/analyse , Indoles/composition chimique , Chromatographie en phase liquide à haute performance/méthodes , Contamination de médicament , Conformation moléculaire
3.
J Pharm Pharmacol ; 54(5): 689-98, 2002 May.
Article de Anglais | MEDLINE | ID: mdl-12005364

RÉSUMÉ

Preparation, pharmacological properties and structure-activity relationships of new pyrimidyl-piperazine derivatives, exhibiting sedative and hypnotic activity in mice, are reported. The hypnotic activity of the compounds was comparable with that of zopiclone (the known hypnotic-sedative agent), their interaction with ethanol, however, being much lower. The obtained results suggested that zopiclone and pyrimidylpiperazines 2, 4 and 5 exerted their pharmacological activity through a different mechanism - zopiclone through the interaction with benzodiazepine receptors and compounds 2, 4 and 5 through an unidentified molecular target. The pharmacological properties of compound 3 could be the result of a mixed mechanism of action, combining the properties of zopiclone and those of compounds 2, 4 and 5. A common feature of zopiclone and compounds 2 and 3 was that, after their systemic administration, independently of mechanism of action, together with the hypnotic effect a reduction of the 5-HT turnover in the mouse brain was observed. Minimum structural requirements for the hypnotic activity were formulated. Structural considerations have shown that removing the alpha-carbonyl group did not influence the drug's ability to inhibit the locomotor activity. However, it did influence its ability to disturb motor coordination or abolish the righting reflex within non-lethal doses.


Sujet(s)
Comportement animal/effets des médicaments et des substances chimiques , Hypnotiques et sédatifs/composition chimique , Hypnotiques et sédatifs/pharmacologie , Pipérazines/composition chimique , Pipérazines/pharmacologie , Animaux , Chimie du cerveau/effets des médicaments et des substances chimiques , Chromatographie en phase liquide à haute performance , Acide 5-hydroxy-indole-3-acétique/analyse , Hypnotiques et sédatifs/toxicité , Dose létale 50 , Mâle , Souris , Pipérazines/toxicité , Rats , Rat Wistar , Récepteurs GABA , Récepteurs aux neuromédiateurs/métabolisme , Sérotonine/analyse , Relation structure-activité
4.
Farmaco ; 57(4): 285-301, 2002 Apr.
Article de Anglais | MEDLINE | ID: mdl-11989808

RÉSUMÉ

In the present paper, we describe affinities to 5-HT1A and 5-HT2A receptors of several new 1,2,4-trisubstituted piperazine derivatives. The affinities were compared with those described earlier for 1,4-disubstituted piperazines and the influence of the third (methyl) substituent on the affinity to both receptors is discussed. The difference between two- and three-substituted derivatives was rationalised in terms of molecular modelling of the respective ligand-receptor complexes. Additionally, the functional activity of some 1,2,4-trisubstituted piperazines for 5-HT1A receptor was examined in behavioural and biochemical models. The obtained results have shown that some trisubstituted compounds exhibited a higher affinity to 5-HT2A receptors than their respective disubstituted analogues (with the affinity to 5-HT1A receptors remaining the same or somewhat improving). The molecular dynamics simulations suggested that the presence of the third substituent in the piperazine ring of those compounds may induce stabilising effect on the ligand-receptor complexes. The results of the in vivo studies have shown that some of the examined trisubstituted piperazines (10-13, 16, 17) exhibited properties of postsynaptic 5-HT1A partial agonists. Moreover, compounds 13 and 16 exhibited features of 5-HT1A presynaptic agonists in in vitro test, and compound 16 also in in vivo tests.


Sujet(s)
Pipérazines/composition chimique , Récepteurs sérotoninergiques/effets des médicaments et des substances chimiques , Antisérotonines/composition chimique , Agonistes des récepteurs de la sérotonine/composition chimique , Animaux , Comportement animal/effets des médicaments et des substances chimiques , Fixation compétitive , Température du corps/effets des médicaments et des substances chimiques , Encéphale/effets des médicaments et des substances chimiques , Encéphale/métabolisme , Techniques in vitro , Ligands , Mâle , Souris , Modèles moléculaires , Pipérazines/pharmacologie , Dosage par compétition , Rats , Rat Wistar , Récepteur de la sérotonine de type 5-HT2A , Récepteurs de la sérotonine de type 5-HT1 , Antisérotonines/pharmacologie , Agonistes des récepteurs de la sérotonine/pharmacologie , Relation structure-activité
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE